Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RN7SL704P is a nonfunctional pseudogene derived from the 7SL RNA gene, which encodes the RNA component of the signal recognition particle (SRP)[1][3][6]. The SRP is a ribonucleoprotein complex essential for targeting secretory and membrane proteins to the endoplasmic reticulum in eukaryotes[1][5]. However, RN7SL704P itself does not encode a functional RNA or protein, is not expressed as a gene product, and is not involved in any known biological, pathological, or therapeutic processes. Like most processed pseudogenes, it is the product of retrotransposition, where a copy of the original RNA was re-inserted and accumulated disabling mutations, resulting in the loss of function[3][6]. There is no evidence that RN7SL704P is involved in disease or relevant for drug development. RN7SL704P is a pseudogene—it is not an active gene, enzyme, receptor, or functional biomolecule for standard drug targeting. It does not encode a functional RNA or protein, nor does it have any direct, known therapeutic relevance[2][3][6]. Pseudogenes are nonfunctional genomic elements—they resemble genes but have lost their gene expression capability due to mutations or truncations[6]. Pseudogenes such as some 7SL-derived sequences may occasionally play a minor role in gene regulation by acting as decoys/sponges for miRNAs or participating in regulatory networks through sequence homology, but there is no specific evidence for RN7SL704P having such a role[4]. If you are interested in the functional 7SL RNA (e.g., the "signal recognition particle RNA"), that is a distinct functional non-coding RNA, but RN7SL704P refers only to a nonfunctional pseudogene variant[1][2][3][6].
None
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, 7SL, cytoplasmic 704, pseudogene (RN7SL704P).